Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Core Viewpoint - Trevi Therapeutics, Inc. has announced a public offering of 12,500,000 shares of its common stock at a price of $4.00 per share, aiming to raise total proceeds of$50 million before expenses [1] Group 1: Offering Details - The offering is fully underwritten and is expected to close on December 17, 2024, subject to customary closing conditions [1] - The shares are being sold under a shelf registration statement filed with the SEC, which was declared effective on August 15, 2023 [3] - The final terms of the offering will be disclosed in a prospectus supplement to be filed with the SEC [3] Group 2: Investor Participation - The financing includes participation from both new and existing investors, such as Adage Capital Partners LP, Frazier Life Sciences, and others [2] - Leerink Partners, Stifel, and Oppenheimer & Co. are acting as joint book-running managers for the offering, with Needham & Company as the lead manager [2] Group 3: Company Overview - Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [5] - Haduvio acts on the cough reflex arc as a kappa agonist and mu antagonist, targeting opioid receptors involved in cough hypersensitivity [5]